NYVAC-based plasmodium malaria vaccine
AssigneeThe Government of the United States, as represented by the Secretary of the Army
InventorsKevin D. Hauns, Farheen Ahmed, Saba Alemayehu
Life of this patent
Estimating the term…
Abstract
The disclosure generally provides a WRrNYVAC comprising multiple antigens from different stages of a malaria parasite (Plasmodium) life cycle, methods for producing them, immunogenic vaccine formulations comprising WRrNYVAC, such as P. vivax containing formulations (WRPvrNYVAC) and P. falciparum containing formulations (WRPfrNYVAC) and methods for the prevention and/or treatment of malaria infections and poxvirus infections.
Claims26
A recombinant New York vaccinia derived from the Copenhagen strain (rNYVAC) virus capable of expressing a malaria antigen gene, wherein the malaria antigen gene is under the control of a compact synthetic early-late promoter comprising the nucleotide sequence of SEQ ID NO:
- 1 and is inserted into a region of the recombinant New York vaccinia derived from the Copenhagen strain (NYVAC) viral genome selected from the group consisting of:
- A26L, A56R, I4L, J2R, B13/B14R, and C7L-K1L, and wherein the malaria antigen gene encodes a malaria antigen selected from the group consisting of:
- a pre-erythrocytic stage antigen, a blood stage antigen, and a transmission blocking stage antigen.
A recombinant NYVAC virus capable of expressing a Plasmodium falciparum malaria antigen gene selected from the group consisting of:
- AMA1, CelTOS, CS, LSA1-RPTLS, SIAP1, SIAP2, SPATR, SPECT1, SPECT2, STARP, TRAP, EBA175 RII, MSP1-p19, MSP1-p42, MSP1DBL, MSP3, MSP5, MSP7, MSP9, PfSEA1, Rh5, Pfs16, Pfs25, Pfs28, and Pfs48.45, wherein the P. falciparum malaria antigen gene is under the control of a compact synthetic early-late promoter comprising the nucleotide sequence of SEQ ID NO:
- 1 and is inserted into a region of the NYVAC viral genome selected from the group consisting of:
- A26L, A56R, I4L, J2R, and B13/B14R.
A recombinant NYVAC virus capable of expressing a Plasmodium vivax malaria antigen gene selected from the group consisting of:
- CS-VK210, CS-VK247, AMA1, TRAP-SSP2, MSP1 fragment p42, Duffy Binding Protein region II, PVS 28, and PVS 25, wherein the P. vivax malaria antigen gene is under the control of a compact synthetic early-late promoter comprising the nucleotide sequence of SEQ ID NO:
- 1 and is inserted into a region of the NYVAC viral genome selected from the group consisting of A26L, A56R, I4L, J2R, B13/B14R, and C7L-K1L.
Dependencies are inferred from the claim text.